$TORNTPHARM Torrent Pharma’s Q4 FY26 results, announced on 22 May 2026:

Torrent Pharma’s Q4 FY26 results, announced on 22 May 2026: 💊 Torrent Pharmaceuticals Ltd – Q4 FY26 Results Financial Performance Revenue: ₹2,660 crore (▲ 8% YoY) Net Profit: ₹449 crore (▲ 12% YoY) EBITDA: ₹830 crore (▲ 10% YoY) EBITDA Margin: 31% Dividend: ₹25 per share (final) Business Highlights India Business: Strong growth in chronic therapies (cardiac, diabetes, CNS). Brazil & Germany: Steady performance with new product launches. U.S. Market: Recovery driven by new approvals and stable pricing. R&D Spend: ₹180 crore (6.8% of sales). New Launches: Introduced 8 products in India and 3 in the U.S. during Q4. Key Takeaways Torrent Pharma maintained leadership in chronic segments with double‑digit domestic growth. International business diversification continues to support earnings stability. Management outlook for FY27 remains positive with focus on specialty and biosimilar expansion.